Literature DB >> 6331465

Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.

N Taira, M Endoh, T Iijima, K Satoh, T Yanagisawa, S Yamashita, M Maruyama, M Kawada, T Morita, Y Wada.   

Abstract

Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4- dimethoxybenzoyl )-1-piperazinyl]-2(1H)- qu inolinone ( OPC -8212) were investigated exclusively on dogs both in vivo and in vitro. When assessed by intra-arterial administration in isolated, blood-perfused papillary muscle, sinoatrial node and atrioventricular (AV) node preparations, OPC -8212 produced a positive inotropic effect scarcely causing either positive or negative chronotropic and coronary vasodilator effects. AV nodal conduction was slightly facilitated with OPC -8212, whereas ventricular automaticity was rather suppressed. No arrhythmias were produced. Thus, OPC -8212 is highly specific for force. In heart-lung preparations OPC -8212 improved cardiac function depressed with pentobarbital, and caused bradycardia. In trabecular muscles of the right ventricle (hereafter simply called ventricular muscles) OPC -8212 produced a concentration-dependent positive inotropic effect in the presence of the beta 1-adrenoceptor antagonist, atenolol. This indicates that the positive inotropic effect of OPC -8212 is not mediated through a beta-adrenoceptor mechanism. In ventricular muscles OPC -8212 increased plateau potentials of normal action potentials in the presence of atenolol. In K+-depolarized ventricular muscles OPC -8212 increased overshoot potentials and durations of slow response action potentials in the presence of atenolol. These suggest an increase in the slow inward current to underlie the positive inotropic effect of OPC -8212. In ventricular muscles OPC -8212 shortened total duration of contraction and time to peak tension in the presence of atenolol. In ventricular muscles OPC -8212 increased force of contraction and intracellular concentrations of cyclic AMP in a parallel way in time course in the presence of atenolol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331465

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  16 in total

1.  Subcellular mechanism of the positive inotropic effect of a new quinolinone derivative OPC-8490 on the dog ventricular myocardium.

Authors:  M Endoh; H Satoh; I Norota; K Hirano; T Hosokawa
Journal:  Heart Vessels       Date:  1991       Impact factor: 2.037

2.  Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes.

Authors:  Y Momose; S Sasayama
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

3.  T-1583 and forskolin are similar in their cardiac effects and dissimilar in their vascular effects.

Authors:  M Hosono; K Satoh; N Taira
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

4.  Effect of ouabain on the relation between left ventricular oxygen consumption and systolic pressure-volume area (PVA) in dog heart.

Authors:  D Q Wu; Y Yasumura; T Nozawa; N Tanaka; S Futaki; Y Ohgoshi; H Yaku; H Suga
Journal:  Heart Vessels       Date:  1989       Impact factor: 2.037

5.  Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity.

Authors:  M Inoue; B H Kim; M Hori; Y Tsuneoka; N Matsubara; T Kamada; K Kodama; M Naka; S Nanto; Y Higashino
Journal:  Heart Vessels       Date:  1986       Impact factor: 2.037

6.  A new cardiotonic agent, OPC-8212, elevates the myocardial oxygen consumption versus pressure-volume area (PVA) relation in a similar manner to catecholamines and calcium in canine hearts.

Authors:  S Futaki; T Nozawa; Y Yasumura; N Tanaka; H Suga
Journal:  Heart Vessels       Date:  1988       Impact factor: 2.037

7.  Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias.

Authors:  K Hashimoto; H Mitsuhashi
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

8.  A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

9.  Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.

Authors:  T Hosokawa; T Mori; H Fujiki; S Kinoshita; K Takemoto; T Imaizumi; T Noda; M Ohura; M Tominaga; Y Yabuuchi
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

10.  OPC-8212 in the treatment of congestive heart failure: results of a pilot study.

Authors:  S H Kubo; T S Rector; J E Strobeck; J N Cohn
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.